Stockholders' Equity

12 Months Ended

Dec. 31, 2024

Share-Based Payment Arrangement, Noncash Expense [Abstract]

Stockholders’ Equity

The Company recognizes stock-based compensation in accordance with the provisions of ASC Topic 718, Compensation-Stock Compensation. Stock-based compensation expense was $2,019 and $2,044, excluding $7 and $34 of compensation charges related to our Amended and Restated 1996 Employee Stock Purchase Plan, or the ESPP, for the years ended December 31, 2024 and 2023, respectively.

The Company is authorized to grant stock options, restricted stock awards and other stock-based awards under its Amended and Restated 2016 Equity and Incentive Plan (the 2016 Plan) with respect to up to 6,080 shares of common stock (excluding rollover shares), an increase of 1,280 shares reserved for issuance under the previous 2016 Plan as approved by our shareholders on June 8, 2022. Options have generally been granted with an exercise price equal to the fair market value of the common stock on the date of grant and have generally provided for vesting in equal annual amounts over four years beginning on the first anniversary of the date of the grant. No options are exercisable for periods of more than five years after date of grant. Under the 2016 Plan, each share issued under awards other than options and stock appreciation rights will reduce the number of shares reserved for issuance by two shares. Shares issued under options or stock appreciation rights will reduce the shares reserved for issuance on a share-for-share basis. The Company accounts for forfeitures as they occur. The 2016 Plan and earlier equity compensation plans, pursuant to which an aggregate of 15,495 shares of the Company’s common stock were reserved for issuance, were all approved by the Company’s shareholders. As of December 31, 2024, 1,453 shares were available for future grants. The Compensation Committee of the Board of Directors administers the equity compensation plans, approves the individuals to whom awards will be granted and determines the number of shares and other terms of each award. Outstanding options under the Company’s equity compensation plans at December 31, 2024 expire from August 2025 through February 2029. None of the Company’s outstanding options includes performance-based or market-based vesting conditions as of December 31, 2024.

(a)Employee Stock Options

The Company has estimated the fair value of each option grant on the date of grant using the Black-Scholes option-pricing model. The expected volatility assumption is based on the historical daily price data of the Company’s common stock over a period equivalent to the weighted average expected life of the Company’s options. The expected term of options granted is derived using assumed exercise rates based on historical exercise patterns and represents the period of time the options granted are expected to be outstanding. The risk-free interest rate is based on the actual U.S. Treasury zero-coupon rates for bonds matching the expected term of the option as of the option grant date. The dividend yield of zero is based upon the fact that the Company has not historically declared or paid cash dividends, and does not expect to declare or pay dividends in the foreseeable future.

The per share weighted-average fair values of stock options granted during 2024 and 2023 were $2.23 and $4.06, respectively. The weighted-average assumptions used to value options as of their grant date were as follows:


	Year Ended December 31,
	2024		2023
Risk-free interest rate	4.36	%	4.49	%
Expected volatility	48.63	%	43.93	%
Expected life (in years)	4.32		4.30

Dividend yield	0	%	0	%

The changes in outstanding stock options for the years ended December 31, 2024 and 2023 are as follows:


	Number of Options	Weighted Average Exercise Price		Weighted Average Remaining Contractual Life (in Years)	Aggregate Intrinsic Value
Outstanding at December 31, 2023	1,230	$	9.57
Granted	266	$	5.03
Exercised	—	$	—
Expired, canceled or forfeited	(542)	$	9.62
Outstanding at December 31, 2024	954	$	8.27	2.56	$	—
Exercisable at December 31, 2024	410	$	9.33	1.53	$	—
Options vested or expected to vest at December 31, 2024	954	$	8.27	2.56	$	—


	Number of Options	Weighted Average Exercise Price		Weighted Average Remaining Contractual Life (in Years)	Aggregate Intrinsic Value
Outstanding at December 31, 2022	1,751	$	9.77
Granted	317	$	9.81
Exercised	(274)	$	9.07
Expired, canceled or forfeited	(564)	$	10.58
Outstanding at December 31, 2023	1,230	$	9.57	2.67	$	—
Exercisable at December 31, 2023	510	$	9.56	1.63	$	—
Options vested or expected to vest at December 31, 2023	1,230	$	9.57	2.67	$	—

No options were exercised during 2024. The total aggregate intrinsic value of options exercised in 2023 was $542.

As of December 31, 2024, there was $1,174 of total unrecognized compensation expense related to stock options, which is expected to be recognized over a weighted-average period of 2.34 years. In 2024 and 2023, the Company recorded compensation charges of $710 and $774, respectively, related to stock options. Compensation costs for options subject only to service conditions that vest ratably are recognized on a straight-line basis over the requisite service period for the entire award. During 2024 and 2023, cash received under stock option plans for exercises was $0 and $2,480, respectively.

(b)Restricted Stock

The Company granted 207 and 217 restricted stock awards to employees under the terms of the 2016 Plan for the years ended December 31, 2024 and 2023, respectively. The restricted stock awards have generally provided for vesting annually over four years from the date of grant subject to the recipient remaining an employee through the applicable vesting dates. Compensation expense for restricted stock awards is measured at fair value on the date of grant based on the number of shares granted and the quoted market closing price of the Company’s common stock. Such value is recognized as expense over the vesting period of the award, net of forfeitures. The weighted-average grant-date fair value of restricted stock granted during 2024 and 2023 was $4.82 and $9.49 per share, respectively.

As of December 31, 2024, there was $1,609 of total unrecognized compensation expense related to restricted stock awards, which is expected to be recognized over a weighted-average period of 2.04 years. Compensation costs for awards subject only to service conditions that vest ratably are recognized on a straight-line basis over the requisite service period for the entire award. Compensation cost for awards initially subject to certain performance conditions are recognized on a ratable basis over the requisite service period for the entire award. In 2024 and 2023, the Company recorded compensation charges of $1,310 and $1,270, respectively, related to restricted stock awards.

Restricted stock activity under the 2016 Plan for 2024 and 2023 are as follows:


	Number of Shares	Weighted- average grant date fair value
Outstanding at December 31, 2023, unvested	355	$	9.34
Granted	207	4.82
Vested	(181)	8.71
Forfeited	(61)	8.53
Outstanding at December 31, 2024, unvested	320	$	6.92


	Number of Shares	Weighted- average grant date fair value
Outstanding at December 31, 2022, unvested	326	$	9.30
Granted	217	9.49
Vested	(116)	9.21
Forfeited	(72)	9.80
Outstanding at December 31, 2023, unvested	355	$	9.34

(c)Common Stock Repurchase

During 2024, no shares of common stock were repurchased. During 2023, the Company’s Board of Directors authorized the repurchase of a portion of executive common stock. The company repurchased 23 shares of common stock held by executives at the Company to satisfy minimum tax withholding obligations in lieu of cash payment.

(d)Employee Stock Purchase Plan

Under the Company’s ESPP, an aggregate of 1,650 shares of common stock have been reserved for issuance, of which 735 shares remain available as of December 31, 2024.

The ESPP covers all of the Company’s employees. Under the terms of the ESPP, eligible employees can elect to have up to six percent of their pre-tax compensation withheld to purchase shares of the Company’s common stock on a semi-annual basis at 85% of the market price on the first or last day of each purchase period, whichever is lower. During 2024 and 2023, shares issued under this plan were 27 and 17 shares, respectively. The Company utilizes the Black-Scholes option-pricing model to calculate the fair value of these discounted purchases. The fair value of the 15% discount is recognized as compensation expense over the purchase period. The Company applies a graded vesting approach because the ESPP provides for multiple purchase periods and is, in substance, a series of linked awards. In 2024 and 2023, the Company recorded compensation charges of $7 and $34, respectively, related to the ESPP. During 2024 and 2023, cash received under the ESPP was $110 and $124, respectively.

(e)Stock-Based Compensation Expense

The following presents stock-based compensation expense, including expense for the ESPP, in the Company’s consolidated statements of operations for the years ended December 31, 2024 and 2023.


	2024		2023
Cost of service sales	$	29	$	21
Cost of product sales	23		34
Research and development	378		567
Sales, marketing and support	293		222
General and administrative	1,304		1,234
	$	2,027	$	2,078

(f) Accumulated Other Comprehensive Loss (AOCL)

Comprehensive loss includes net loss and unrealized gains and losses from foreign currency translation. The components of the Company’s comprehensive loss and the effect on earnings for the periods presented are detailed in the accompanying consolidated statements of comprehensive loss.


	Foreign Currency Translation		Unrealized (Loss) Income on Available for Sale Marketable Securities		Total Accumulated Other Comprehensive Loss
Balance, December 31, 2022	$	(4,098)	$	(12)	$	(4,110)
Other comprehensive (loss) income	(87)		12		(75)

Net other comprehensive (loss) income	(87)		12		(75)
Balance, December 31, 2023	(4,185)		—		(4,185)
Other comprehensive income	153		—		153
Net other comprehensive income	153		—		153
Balance, December 31, 2024	$	(4,032)	$	—	$	(4,032)